Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG-CSF

Bone Marrow Transplantation

Volumn 32, Issue 1, 2003, Pages 31-34

  Kaplinsky, C ^a   Trakhtenbrot, L ^a   Hardan, I ^a,b   Reichart, M ^c   Daniely, M ^c   Toren, A ^a   Amariglio, N ^a   Rechavi, G ^a   Izraeli, S ^a  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c BIOVIEW LTD   (Israel)

Author keywords

Cytogenetics; G CSF; Peripheral stem cell harvest; Peripheral stem cell transplantation; Tetraploidy

Indexed keywords

CD34 ANTIGEN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ARTICLE; BONE MARROW CELL; CELL STRUCTURE; CELL SUBPOPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIPLOIDY; DONOR; GENOTYPE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; NUMERICAL CHROMOSOME ABERRATION; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; STEM CELL MOBILIZATION; T LYMPHOCYTE; TETRAPLOIDY;

CASE-CONTROL STUDIES; CELL SIZE; CHROMOSOME ABERRATIONS; CYTOGENETIC ANALYSIS; DRUG EVALUATION; FEMALE; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; GRANULOCYTE PRECURSOR CELLS; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; LEUKAPHERESIS; LYMPHOMA; MALE; MYELOID CELLS; NEUTROPHILS; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; POLYPLOIDY; TISSUE DONORS;

EID: 0037817611     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703902     Document Type: Article

References (20)

1. Welte K, Gabrilove J, Bronchud MH et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996; 88: 1907-1929.
2. Link DC. Mechanisms of granulocyte colony-stimulating factor-induced hematopoietic progenitor-cell mobilization. Semin Hematol 2000; 37: 25-32.
3. Cleaver SA, Goldman JM. Use of G-CSF to mobilise PBSC in normal healthy donors-an international survey. Bone Marrow Transplant 1998; 21 (Suppl. 3): S29-S31.
4. Price TH. The use of G-CSF in normal neutrophil donors. Ann Med Interne (Paris) 2000; 151: 115-122.
5. Volk EE, Domen RE, Smith ML. An examination of ethical issues raised in the pretreatment of normal volunteer granulocyte donors with granulocyte colony-stimulating factor. Arch Pathol Lab Med 1999; 123: 508-513.
6. Anderlini P, Donato M, Chan KW et al. Allogeneic blood progenitor cell collection in normal donors after mobilization with filgrastim: the M.D. Anderson Cancer Center experience. Transfusion 1999; 39: 555-560.
7. Anderlini P, Korbling M, Dale D et al. Allogeneic blood stem cell transplantation: considerations for donors. Blood 1997; 90: 903-908.
8. Tidow N, Kasper B, Welte K. Clinical implications of G-CSF receptor mutations. Crit Rev Oncol Hematol 1998; 28: 1-6.
9. Stroncek D, Anderlini P. Mobilized PBPC concentrates: a maturing blood component. Transfusion 2001; 41: 168-171.
10. Stroncek DF, Yau YY, Oblitas J, Leitman SF. Administration of G-CSF plus dexamethasone produces greater granulocyte concentrate yields while causing no more donor toxicity than G-CSF alone. Transfusion 2001; 41: 1037-1044.
11. Platzbecker U, Prange-Krex G, Bornhauser M et al. Spleen enlargement in healthy donors during G-CSF mobilization of PBPCs. Transfusion 2001; 41: 184-189.
12. Campbell LJ, Maher DW, Tay DL et al. Marrow proliferation and the appearance of giant neutrophils in response to recombinant human granulocyte colony stimulating factor (rhG-CSF). Br J Haematol 1992; 80: 298-304.
13. Ulich TR, del Castillo J, Souza L. Kinetics and mechanisms of recombinant human granulocyte-colony stimulating factor-induced neutrophilia. Am J Pathol 1988; 133: 630-638.
14. Shimoni A, Nagler A, Kaplinsky C et al. Chimerism testing and detection of minimal residual disease after allogeneic hematopoietic transplantation using the bioView (Duet) combined morphological and cytogenetical analysis. Leukemia 2002; 16: 1413-1418; discussion 1419-1422.
15. Bielorai B, Golan H, Trakhtenbrot L et al. Combined analysis of morphology and FISH in follow-up of minimal residual disease (MRD) in a child with ph+ acute lymphoblastic leukemia. Cancer Genet Cytogenet 2002; 138: 64-68.
16. Jakubowski A, Gabrilove J. Granulocyte colony stimulating factor (G-CSF): biology and clinical status. Cancer Biother Radiopharm 1996; 11: 5-20.
17. Clarke DJ, Gimenez-Abian JF. Checkpoints controlling mitosis. Bioessays 2000; 22: 351-363.
18. Schmidt-Mende J, Tehranchi R, Forsblom AM et al. Granulocyte colony-stimulating factor inhibits Fas-triggered apoptosis in bone marrow cells isolated from patients with refractory anemia with ringed sideroblasts. Leukemia 2001; 15: 742-751.
19. Villunger A, O'Reilly LA, Holler N et al. Fas ligand, Bcl-2, granulocyte colony-stimulating factor, and p38 mitogen-activated protein kinase: regulators of distinct cell death and survival pathways in granulocytes. J Exp Med 2000; 192: 647-658.
20. Kaplinsky C, Lotem J, Sachs L. Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granulocyte-macrophage colony-stimulating factor and interleukin 3. Leukemia 1996; 10: 460-465.